A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE MOCERTATUG REZETECAN WITH BEVACIZUMAB COMPARED WITH PLATINUM DOUBLET WITH BEVACIZUMAB IN PARTICIPANTS WITH PLATINUM-SENSITIVE OVARIAN CANCER
- Registry ID
- 224040
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- GLAXOSMITHKLINE INC
- Last update
- 2026-07-03
Conditions
- PLATINUM-RESISTANT OVARIAN CANCER
Related clinical trials
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE
TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER
SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH
PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
- MULTI-ARM PHASE 2 STUDY OF UBAMATAMAB (REGN4018; MUC16×CD3 BISPECIFIC ANTIBODY) WITH OR WITHOUT ADDITIONAL AGENTS IN PLATINUM-RESISTANT OVARIAN
CANCER
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
- A MULTICENTER, OPEN-LABEL, PARALLEL, PHASE 2A STUDY OF PLX2853 MONOTHERAPY IN ADVANCED GYNECOLOGICAL MALIGNANCIES WITH A KNOWN ARID1A MUTATION AND PHASE 1B/2A STUDY OF PLX2853/CARBOPLATIN COMBINATION THERAPY IN PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER
- PHASE 1 (SAFETY ASSESSMENT) OF DURVALUMAB (MEDI4736) WITH FOCAL SENSITIZING RADIOTHERAPY IN PLATINUM RESISTANT OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE EPITHELIAL CARCINOMA
- A PHASE 1/2, OPEN-LABEL SAFETY AND EFFICACY EVALUATION OF CRS-207 IN COMBINATION WITH EPACADOSTAT IN ADULTS WITH PLATINUM-RESISTANT OVARIAN, FALLOPIAN, OR PERITONEAL CANCER
View on source registry